Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2021 07:00 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Presents Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented a...
November 10, 2021 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
November 09, 2021 16:01 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
November 04, 2021 09:00 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
October 26, 2021 16:15 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Announces Change to Management Team and Board of Directors

Julie Eastland Appointed President and Chief Executive Officer Jerry McMahon, Ph.D., Resigns from Harpoon as President and Chief Executive Officer Scott Myers, Current Member of Harpoon’s Board of...
October 05, 2021 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
September 02, 2021 07:30 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
August 05, 2021 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Presented updated interim Phase 1/2a clinical trial data for PSMA-targeting TriTAC® HPN424 in prostate cancer at ASCO Annual Meeting Provided clinical trial updates for three additional TriTAC...
August 03, 2021 16:05 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
June 04, 2021 16:00 ET | Source: Harpoon Therapeutics

Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life...